Dr. Kleanthis Xanthopoulos, CEO of Regulus Therapeutics Inc (RGLS), says the reason the company decided to separate its research division is because the technology, which was originally started to support its own therapeutic programs, turned out to have more utilities than management had anticipated. He says the research division attracted interest from a number of partners.
“We at Regulus want to focus exclusively on therapeutics, not biomarkers or diagnostics, but we want to use this technology for a lot of our clinical studies for stratifying patients, such as identifying clinical biomarkers that follow the effect of a specific drug,” Xanthopoulos says. “So with the Biogen Idec deal of 2012 and the extension that was announced recently, we see the possibility of that division growing and ultimately standing on its own right as an independent unit or even within the current business.”
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Xanthopoulos says one of Regulus’ top goals is to develop a greater understanding of how drugs change in terms of microRNA once they are in a patient’s bloodstream.
“It would be terrific if we can develop signatures, if you like, that can predict that this particular individual is going to be positively responding to which drug versus not responding. And of course, you now take all the therapeutic indications and all the drugs that are in the market or in development, and there is a tremendous business opportunity,” Xanthopoulos says. “So that’s what we want to be focusing on. We don’t want to enable other companies to compete with us on the therapeutic front. That’s the space that we completely want to dominate.”
New Trends in Communication Semiconductors Separate Winners from Losers
February 23, 2010
Actavis (ACT) Has Large Exposure to Generic Drugs in Alternative Dosage Forms
May 01, 2013
Wireless Division of ARC Group WorldWide Inc (ARCW) Eyes Growth Via Acquisition
July 24, 2014
Government/Academic Research May Mean Greater Upside to Life Sciences Companies
January 27, 2010
Recommended Reading – CEO Succession Planning Lags Badly Research Finds, Stanford Graduate School of Business
June 17, 2010
